Skip to main content
PMC home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1989 Oct;84(4):1063–1069. doi: 10.1172/JCI114268

Biochemical and clinical response of fulminant viral hepatitis to administration of prostaglandin E. A preliminary report.

S B Sinclair 1, P D Greig 1, L M Blendis 1, M Abecassis 1, E A Roberts 1, M J Phillips 1, R Cameron 1, G A Levy 1
PMCID: PMC329761  PMID: 2794044

Abstract

The effect of PG on patients with fulminant and subfulminant viral hepatitis (FHF) was studied. 17 patients presented with FHF secondary to hepatitis A (n = 3), hepatitis B (n = 6), and non-A, non-B (NANB) hepatitis (n = 8). 14 of the 17 patients had stage III or IV hepatic encephalopathy (HE). At presentation the mean aspartate transaminase (AST) was 1,844 +/- 1,246 U/liter, bilirubin 232 +/- 135 mumol/liter, prothrombin time (PT) 34 +/- 18, partial thromboplastin time (PTT) 73 +/- 26 s, and coagulation Factors V and VII 8 +/- 4 and 9 +/- 5%, respectively. Intravenous PGE1 was initiated 24-48 h later after a rise in AST (2,195 +/- 1,810), bilirubin (341 +/- 148), PT (36 +/- 15), and PTT (75 +/- 18). 12 of 17 responded rapidly with a decrease in AST from 1,540 +/- 833 to 188 +/- 324 U/liter. Improvement in hepatic synthetic function was indicated by a decrease in PT from 27 +/- 7 to 12 +/- 1 s and PTT from 61 +/- 10 to 31 +/- 2 s, and an increase in Factor V from 9 +/- 4 to 69 +/- 18% and Factor VII from 11 +/- 5 to 71 +/- 20%. Five responders with NANB hepatitis relapsed upon discontinuation of therapy, with recurrence of HE and increases in AST and PT, and improvement was observed upon retreatment. After 4 wk of intravenous therapy oral PGE2 was substituted. Two patients with NANB hepatitis recovered completely and remained in remission 6 and 12 mo after cessation of therapy. Two additional patients continued in remission after 2 and 6 mo of PGE2. No relapses were seen in the patients with hepatitis A virus and hepatitis B virus infection. Liver biopsies in all 12 surviving patients returned to normal. In the five nonresponders an improvement in hepatic function was indicated by a fall in AST (3,767 +/- 2,611 to 2,142 +/- 2,040 U/liter), PT (52 +/- 25 to 33 +/- 18 s), and PTT (103 +/- 29 to 77 +/- 44 s), but all deteriorated and died of cerebral edema (n = 3) or underwent liver transplantation (n = 2). These results suggest efficacy of PGE for FHF, and further investigation is warranted.

Full text

PDF
1063

Images in this article

1066Image
on p.1066

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abecassis M., Falk J. A., Makowka L., Dindzans V. J., Falk R. E., Levy G. A. 16, 16 Dimethyl prostaglandin E2 prevents the development of fulminant hepatitis and blocks the induction of monocyte/macrophage procoagulant activity after murine hepatitis virus strain 3 infection. J Clin Invest. 1987 Sep;80(3):881–889. doi: 10.1172/JCI113147. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Abecassis M., Falk J., Dindzans V., Lopatin W., Makowka L., Levy G., Falk R. Prostaglandin E2 prevents fulminant hepatitis and the induction of procoagulant activity in susceptible animals. Transplant Proc. 1987 Feb;19(1 Pt 2):1103–1105. [PubMed] [Google Scholar]
  3. Alp M. H., Hickman R. The effect of prostaglandins, branched-chain amino acids and other drugs on the outcome of experimental acute porcine hepatic failure. J Hepatol. 1987 Feb;4(1):99–107. doi: 10.1016/s0168-8278(87)80016-8. [DOI] [PubMed] [Google Scholar]
  4. Auslander M. O., Gitnick G. L. Vigorous medical management of acute fulminant hepatitis. Arch Intern Med. 1977 May;137(5):599–601. [PubMed] [Google Scholar]
  5. Berk P. D., Goldberg J. D. Charcoal hemoperfusion. Plus ça change, plus c'est la même chose. Gastroenterology. 1988 May;94(5 Pt 1):1228–1230. [PubMed] [Google Scholar]
  6. Bernuau J., Rueff B., Benhamou J. P. Fulminant and subfulminant liver failure: definitions and causes. Semin Liver Dis. 1986 May;6(2):97–106. doi: 10.1055/s-2008-1040593. [DOI] [PubMed] [Google Scholar]
  7. Bismuth H., Samuel D., Gugenheim J., Castaing D., Bernuau J., Rueff B., Benhamou J. P. Emergency liver transplantation for fulminant hepatitis. Ann Intern Med. 1987 Sep;107(3):337–341. doi: 10.7326/0003-4819-107-2-337. [DOI] [PubMed] [Google Scholar]
  8. Bourne H. R., Lichtenstein L. M., Melmon K. L., Henney C. S., Weinstein Y., Shearer G. M. Modulation of inflammation and immunity by cyclic AMP. Science. 1974 Apr 5;184(4132):19–28. doi: 10.1126/science.184.4132.19. [DOI] [PubMed] [Google Scholar]
  9. Conn H. O. Trailmaking and number-connection tests in the assessment of mental state in portal systemic encephalopathy. Am J Dig Dis. 1977 Jun;22(6):541–550. doi: 10.1007/BF01072510. [DOI] [PubMed] [Google Scholar]
  10. Davis D. C., Potter W. Z., Jollow D. J., Mitchell J. R. Species differences in hepatic glutathione depletion, covalent binding and hepatic necrosis after acetaminophen. Life Sci. 1974 Jun 1;14(11):2099–2109. doi: 10.1016/0024-3205(74)90092-7. [DOI] [PubMed] [Google Scholar]
  11. Dienstag J. L. Non-A, non-B hepatitis. I. Recognition, epidemiology, and clinical features. Gastroenterology. 1983 Aug;85(2):439–462. [PubMed] [Google Scholar]
  12. Dusheiko G., Dibisceglie A., Bowyer S., Sachs E., Ritchie M., Schoub B., Kew M. Recombinant leukocyte interferon treatment of chronic hepatitis B. Hepatology. 1985 Jul-Aug;5(4):556–560. doi: 10.1002/hep.1840050406. [DOI] [PubMed] [Google Scholar]
  13. Fantone J. C., Kunkel S. L., Ward P. A., Zurier R. B. Suppression by prostaglandin E1 of vascular permeability induced by vasoactive inflammatory mediators. J Immunol. 1980 Dec;125(6):2591–2596. [PubMed] [Google Scholar]
  14. Franco A., Barnaba V., Natali P., Balsano C., Musca A., Balsano F. Expression of class I and class II major histocompatibility complex antigens on human hepatocytes. Hepatology. 1988 May-Jun;8(3):449–454. doi: 10.1002/hep.1840080302. [DOI] [PubMed] [Google Scholar]
  15. Gazzard B. G., Portmann B., Murray-Lyon I. M., Williams R. Causes of death in fulminant hepatic failure and relationship to quantitative histological assessment of parenchymal damage. Q J Med. 1975 Oct;44(176):615–626. [PubMed] [Google Scholar]
  16. Ham E. A., Soderman D. D., Zanetti M. E., Dougherty H. W., McCauley E., Kuehl F. A., Jr Inhibition by prostaglandins of leukotriene B4 release from activated neutrophils. Proc Natl Acad Sci U S A. 1983 Jul;80(14):4349–4353. doi: 10.1073/pnas.80.14.4349. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Hoofnagle J. H., Mullen K. D., Jones D. B., Rustgi V., Di Bisceglie A., Peters M., Waggoner J. G., Park Y., Jones E. A. Treatment of chronic non-A,non-B hepatitis with recombinant human alpha interferon. A preliminary report. N Engl J Med. 1986 Dec 18;315(25):1575–1578. doi: 10.1056/NEJM198612183152503. [DOI] [PubMed] [Google Scholar]
  18. Lands W. E. The biosynthesis and metabolism of prostaglandins. Annu Rev Physiol. 1979;41:633–652. doi: 10.1146/annurev.ph.41.030179.003221. [DOI] [PubMed] [Google Scholar]
  19. Massa P. T., Dörries R., ter Meulen V. Viral particles induce Ia antigen expression on astrocytes. Nature. 1986 Apr 10;320(6062):543–546. doi: 10.1038/320543a0. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Mathiesen L. R., Skinoj P., Nielsen J. O., Purcell R. H., Wong D., Ranek L. Hepatitis type A, B, and non-A non-B in fulminant hepatitis. Gut. 1980 Jan;21(1):72–77. doi: 10.1136/gut.21.1.72. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Mizoguchi Y., Tsutsui H., Miyajima K., Sakagami Y., Seki S., Kobayashi K., Yamamoto S., Morisawa S. The protective effects of prostaglandin E1 in an experimental massive hepatic cell necrosis model. Hepatology. 1987 Nov-Dec;7(6):1184–1188. doi: 10.1002/hep.1840070603. [DOI] [PubMed] [Google Scholar]
  22. Noda Y., Hughes R. D., Williams R. Effect of prostacyclin (PGI2) and a prostaglandin analogue BW 245C on galactosamine-induced hepatic necrosis. J Hepatol. 1986;2(1):53–64. doi: 10.1016/s0168-8278(86)80008-3. [DOI] [PubMed] [Google Scholar]
  23. O'Grady J. G., Gimson A. E., O'Brien C. J., Pucknell A., Hughes R. D., Williams R. Controlled trials of charcoal hemoperfusion and prognostic factors in fulminant hepatic failure. Gastroenterology. 1988 May;94(5 Pt 1):1186–1192. doi: 10.1016/0016-5085(88)90011-x. [DOI] [PubMed] [Google Scholar]
  24. Peleman R. R., Gavaler J. S., Van Thiel D. H., Esquivel C., Gordon R., Iwatsuki S., Starzl T. E. Orthotopic liver transplantation for acute and subacute hepatic failure in adults. Hepatology. 1987 May-Jun;7(3):484–489. doi: 10.1002/hep.1840070312. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Rakela J., Redeker A. G., Edwards V. M., Decker R., Overby L. R., Mosley J. W. Hepatits A virus infection in fulminant hepatitis and chronic active hepatitis. Gastroenterology. 1978 May;74(5 Pt 1):879–882. [PubMed] [Google Scholar]
  26. Rappaport R. S., Dodge G. R. Prostaglandin E inhibits the production of human interleukin 2. J Exp Med. 1982 Mar 1;155(3):943–948. doi: 10.1084/jem.155.3.943. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Rush B., Merritt M. V., Kaluzny M., Van Schoick T., Brunden M. N., Ruwart M. Studies on the mechanism of the protective action of 16,16-dimethylPGE2 in carbon tetrachloride induced acute hepatic injury in the rat. Prostaglandins. 1986 Sep;32(3):439–455. doi: 10.1016/0090-6980(86)90011-0. [DOI] [PubMed] [Google Scholar]
  28. Snyder D. S., Beller D. I., Unanue E. R. Prostaglandins modulate macrophage Ia expression. Nature. 1982 Sep 9;299(5879):163–165. doi: 10.1038/299163a0. [DOI] [PubMed] [Google Scholar]
  29. Stieber A. C., Ambrosino G., Van Thiel D., Iwatsuki S., Starzl T. E. Orthotopic liver transplantation for fulminant and subacute hepatic failure. Gastroenterol Clin North Am. 1988 Mar;17(1):157–165. [PMC free article] [PubMed] [Google Scholar]
  30. Suzumura A., Lavi E., Weiss S. R., Silberberg D. H. Coronavirus infection induces H-2 antigen expression on oligodendrocytes and astrocytes. Science. 1986 May 23;232(4753):991–993. doi: 10.1126/science.3010460. [DOI] [PubMed] [Google Scholar]
  31. Tandon B. N., Joshi Y. K., Krishnamurthy L., Tandon H. D. Subacute hepatic failure; is it a distinct entity? J Clin Gastroenterol. 1982 Aug;4(4):343-6, 362-4. doi: 10.1097/00004836-198208000-00010. [DOI] [PubMed] [Google Scholar]
  32. Tripp C. S., Wyche A., Unanue E. R., Needleman P. The functional significance of the regulation of macrophage Ia expression by endogenous arachidonate metabolites in vitro. J Immunol. 1986 Dec 15;137(12):3915–3920. [PubMed] [Google Scholar]
  33. Tygstrup N., Ranek L. Assessment of prognosis in fulminant hepatic failure. Semin Liver Dis. 1986 May;6(2):129–137. doi: 10.1055/s-2008-1040596. [DOI] [PubMed] [Google Scholar]
  34. Tygstrup N., Ranek L. Fulminant hepatic failure. Clin Gastroenterol. 1981 Jan;10(1):191–208. [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES